Literature DB >> 12955819

Phenylalanine-restricted diet should be life long. A case report on long-term follow-up of an adolescent with untreated phenylketonuria.

Joav Merrick1, Shoshana Aspler, Gerard Schwarz.   

Abstract

The aim of this brief report is to stimulate a debate and to advocate life-long treatment with phenylalanine restricted diet to persons with phenylketonuria. We present a case of an adolescent male who today is a 65 year old with moderate mental retardation. He was previously observed as having severe challenging and self-injurious behaviour, sleeping disorder, hyperactivity, and masturbation. In the last year before reassessment he displayed loss of weight, muscle weakness resulting in wheelchair placement, upper respiratory infections, and fungal skin infections. After reassessment in 1998 the patient was started on treatment with a phenylalanine-restricted diet supplemented with vitamin B12, iron, and folic acid. At follow-up one year later the patient had regained his weight and was walking around freely. The challenging and self-injurious behaviour, and the masturbation, had ceased, and he was participating in social activities which he had previously not been able to participate in. At follow-up four years later he was still at this level of accomplishment. In general, this patient's quality of life had increased. We therefore recommend life-long treatment with phenylalanine restricted diet for persons with previously treated, and also for those with untreated, phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955819     DOI: 10.1515/ijamh.2003.15.2.165

Source DB:  PubMed          Journal:  Int J Adolesc Med Health        ISSN: 0334-0139


  5 in total

1.  Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.

Authors:  H J Vernon; C B Koerner; M R Johnson; A Bergner; A Hamosh
Journal:  Mol Genet Metab       Date:  2010-04-03       Impact factor: 4.797

2.  Management of adult patients with phenylketonuria: survey results from 24 countries.

Authors:  Friedrich K Trefz; Francjan J van Spronsen; Anita MacDonald; François Feillet; Ania C Muntau; Amaya Belanger-Quintana; Alberto Burlina; Mübeccel Demirkol; Marcello Giovannini; Christoph Gasteyger
Journal:  Eur J Pediatr       Date:  2014-12-06       Impact factor: 3.183

3.  Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.

Authors:  Zhaobing Ding; Cary O Harding; Alexandre Rebuffat; Lina Elzaouk; Jon A Wolff; Beat Thöny
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

Review 4.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

5.  Requirements for a minimum standard of care for phenylketonuria: the patients' perspective.

Authors:  Tobias S Hagedorn; Paul van Berkel; Gregor Hammerschmidt; Markéta Lhotáková; Rosalia Pasqual Saludes
Journal:  Orphanet J Rare Dis       Date:  2013-12-17       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.